Cargando…
Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance
Background: Hepatitis C virus infection and interferon treatment have shown to be risk factors for sleep disorder health-related quality of life. Aim: To determine whether the effects of resveratrol on sleep disorders were associated with different tests in subjects with chronic hepatitis C treated...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579690/ https://www.ncbi.nlm.nih.gov/pubmed/28820468 http://dx.doi.org/10.3390/nu9080897 |
_version_ | 1783260760377393152 |
---|---|
author | Pennisi, Manuela Bertino, Gaetano Gagliano, Caterina Malaguarnera, Michele Bella, Rita Borzì, Antonio Maria Madeddu, Roberto Drago, Filippo Malaguarnera, Giulia |
author_facet | Pennisi, Manuela Bertino, Gaetano Gagliano, Caterina Malaguarnera, Michele Bella, Rita Borzì, Antonio Maria Madeddu, Roberto Drago, Filippo Malaguarnera, Giulia |
author_sort | Pennisi, Manuela |
collection | PubMed |
description | Background: Hepatitis C virus infection and interferon treatment have shown to be risk factors for sleep disorder health-related quality of life. Aim: To determine whether the effects of resveratrol on sleep disorders were associated with different tests in subjects with chronic hepatitis C treated with Peg-IFN-α and RBV. Patients and Methods: In this prospective, randomized, placebo controlled, double blind clinical trial, 30 subjects (Group A) with chronic hepatitis received Pegylated-Interferon-α2b (1.5 mg/kg per week), Ribavirin and placebo (N-acetylcysteine 600 mg and lactoferrin 23.6 g), while 30 subjects (Group B) received the same dosage of Pegylated-Interferon-α2b, Ribavirin and association of N-acetylcysteine 600 mg, lactoferrin 23.6 g and Resveratrol 19.8 mg for 12 months. All subjects underwent laboratory exams and questionnaires to evaluate mood and sleep disorders (General Health Questionnaire (GHQ), Profile of Mood States (POMS), Pittsburgh Sleep Quality Inventory (PSQI), Epworth Sleepiness Scale (ESS)). Results: The comparison between Group A and Group B showed significant differences after six months in C-reactive protein (p < 0.0001); after 12 months in aspartate aminotransferase (AST) (p < 0.0001) Viremia (p < 0.0001), HAI (p < 0.0012) and C-reactive protein (p < 0.0001); and at follow up in AST (p < 0.0001), Viremia (p < 0.0026) and C-reactive protein (p < 0.0001). Significant differences were observed after 12 month and follow-up in General Health Questionnaire, after 1, 6, 12 and follow-up in Profile of Mood States, after 6, 12, follow-up in Pittsburgh Sleep Quality Inventory and Epworth Sleepiness Scale. Conclusions: Supplementation with Resveratrol decreased General Health Questionnaire score and reduced sleep disorders in patients treated with Peg–IFN-α and RBV. |
format | Online Article Text |
id | pubmed-5579690 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-55796902017-09-06 Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance Pennisi, Manuela Bertino, Gaetano Gagliano, Caterina Malaguarnera, Michele Bella, Rita Borzì, Antonio Maria Madeddu, Roberto Drago, Filippo Malaguarnera, Giulia Nutrients Article Background: Hepatitis C virus infection and interferon treatment have shown to be risk factors for sleep disorder health-related quality of life. Aim: To determine whether the effects of resveratrol on sleep disorders were associated with different tests in subjects with chronic hepatitis C treated with Peg-IFN-α and RBV. Patients and Methods: In this prospective, randomized, placebo controlled, double blind clinical trial, 30 subjects (Group A) with chronic hepatitis received Pegylated-Interferon-α2b (1.5 mg/kg per week), Ribavirin and placebo (N-acetylcysteine 600 mg and lactoferrin 23.6 g), while 30 subjects (Group B) received the same dosage of Pegylated-Interferon-α2b, Ribavirin and association of N-acetylcysteine 600 mg, lactoferrin 23.6 g and Resveratrol 19.8 mg for 12 months. All subjects underwent laboratory exams and questionnaires to evaluate mood and sleep disorders (General Health Questionnaire (GHQ), Profile of Mood States (POMS), Pittsburgh Sleep Quality Inventory (PSQI), Epworth Sleepiness Scale (ESS)). Results: The comparison between Group A and Group B showed significant differences after six months in C-reactive protein (p < 0.0001); after 12 months in aspartate aminotransferase (AST) (p < 0.0001) Viremia (p < 0.0001), HAI (p < 0.0012) and C-reactive protein (p < 0.0001); and at follow up in AST (p < 0.0001), Viremia (p < 0.0026) and C-reactive protein (p < 0.0001). Significant differences were observed after 12 month and follow-up in General Health Questionnaire, after 1, 6, 12 and follow-up in Profile of Mood States, after 6, 12, follow-up in Pittsburgh Sleep Quality Inventory and Epworth Sleepiness Scale. Conclusions: Supplementation with Resveratrol decreased General Health Questionnaire score and reduced sleep disorders in patients treated with Peg–IFN-α and RBV. MDPI 2017-08-18 /pmc/articles/PMC5579690/ /pubmed/28820468 http://dx.doi.org/10.3390/nu9080897 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Pennisi, Manuela Bertino, Gaetano Gagliano, Caterina Malaguarnera, Michele Bella, Rita Borzì, Antonio Maria Madeddu, Roberto Drago, Filippo Malaguarnera, Giulia Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance |
title | Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance |
title_full | Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance |
title_fullStr | Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance |
title_full_unstemmed | Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance |
title_short | Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance |
title_sort | resveratrol in hepatitis c patients treated with pegylated-interferon-α-2b and ribavirin reduces sleep disturbance |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579690/ https://www.ncbi.nlm.nih.gov/pubmed/28820468 http://dx.doi.org/10.3390/nu9080897 |
work_keys_str_mv | AT pennisimanuela resveratrolinhepatitiscpatientstreatedwithpegylatedinterferona2bandribavirinreducessleepdisturbance AT bertinogaetano resveratrolinhepatitiscpatientstreatedwithpegylatedinterferona2bandribavirinreducessleepdisturbance AT gaglianocaterina resveratrolinhepatitiscpatientstreatedwithpegylatedinterferona2bandribavirinreducessleepdisturbance AT malaguarneramichele resveratrolinhepatitiscpatientstreatedwithpegylatedinterferona2bandribavirinreducessleepdisturbance AT bellarita resveratrolinhepatitiscpatientstreatedwithpegylatedinterferona2bandribavirinreducessleepdisturbance AT borziantoniomaria resveratrolinhepatitiscpatientstreatedwithpegylatedinterferona2bandribavirinreducessleepdisturbance AT madedduroberto resveratrolinhepatitiscpatientstreatedwithpegylatedinterferona2bandribavirinreducessleepdisturbance AT dragofilippo resveratrolinhepatitiscpatientstreatedwithpegylatedinterferona2bandribavirinreducessleepdisturbance AT malaguarneragiulia resveratrolinhepatitiscpatientstreatedwithpegylatedinterferona2bandribavirinreducessleepdisturbance |